4.8 Article

Emergence and rapid transmission of SARS-CoV-2 B.1.1.7 in the United States

期刊

CELL
卷 184, 期 10, 页码 2587-+

出版社

CELL PRESS
DOI: 10.1016/j.cell.2021.03.052

关键词

-

资金

  1. CDC BAA [75D30121P10258, 75D30120C09795]
  2. NIH NIAID [3U19AI135995-03S2, U19AI135995, U01AI151812]
  3. Innovative Genomics Institute
  4. New Frontiers in Research Fund by the Canadian Institutes of Health Research
  5. NIH NCATS [UL1TR002550]

向作者/读者索取更多资源

The highly transmissible B.1.1.7 variant of SARS-CoV-2, first identified in the United Kingdom, has been spreading in the United States with multiple introductions as early as late November 2020. The variant shows a logistic growth rate with roughly weekly doubling and increased transmission, requiring immediate action to minimize COVID-19 morbidity and mortality.
The highly transmissible B.1.1.7 variant of SARS-CoV-2, first identified in the United Kingdom, has gained a foothold across the world. Using S gene target failure (SGTF) and SARS-CoV-2 genomic sequencing, we investigated the prevalence and dynamics of this variant in the United States (US), tracking it back to its early emergence. We found that, while the fraction of B.1.1.7 varied by state, the variant increased at a logistic rate with a roughly weekly doubling rate and an increased transmission of 40%-50%. We revealed several independent introductions of B.1.1.7 into the US as early as late November 2020, with community transmission spreading it to most states within months. We show that the US is on a similar trajectory as other countries where B.1.1.7 became dominant, requiring immediate and decisive action to minimize COVID-19 morbidity and mortality.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据